<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2207">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01549314</url>
  </required_header>
  <id_info>
    <org_study_id>MGH 2012P000269</org_study_id>
    <nct_id>NCT01549314</nct_id>
  </id_info>
  <brief_title>Cystic Fibrosis Related Bone Disease: the Role of CFTR</brief_title>
  <official_title>Cystic Fibrosis Related Bone Disease: the Role of CFTR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ivacaftor, a recently FDA-approved CFTR&#xD;
      potentiator, improves bone micro-architecture and strength in patients with cystic fibrosis&#xD;
      with at least one G551D CFTR mutation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ivacaftor, a CFTR potentiator, has recently been FDA approved for the treatment of cystic&#xD;
      fibrosis in patients with at least one G551D CFTR mutation. Given the possible role of CFTR&#xD;
      in bone, we hypothesize that this medication may also improve bone health in CF patients. The&#xD;
      purpose of this study is to test this hypothesis using high resolution peripheral&#xD;
      quantitative computed tomography, a research tool that measures bone micro-architecture and&#xD;
      volumetric bone density and has the ability to detect small changes in bone that might&#xD;
      otherwise be missed with standard bone imaging techniques such as bone density testing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2012</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Microarchitecture and Strength Measures of the Radius and Tibia</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>Change in cortical volumetric bone mineral density at the radius</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Areal Bone Mineral Density as Measured by DXA</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>Change in PA spine bone mineral density</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Turnover Markers</measure>
    <time_frame>Baseline and 24 months</time_frame>
    <description>Change in osteocalcin</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">79</enrollment>
  <condition>Cystic Fibrosis Related Bone Disease</condition>
  <arm_group>
    <arm_group_label>Subjects with CF taking ivacaftor</arm_group_label>
    <description>Subjects with CF ages 6 to 75 years old who will be or have started taking ivacaftor within the previous 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects with CF not taking ivacaftor</arm_group_label>
    <description>Subjects with CF ages 6 to 75 years old who will not be taking ivacaftor, matched for age, race, and gender with cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <description>Healthy subjects with no medical conditions known to affect bone between the ages of 6 to 75 years old, matched for age, race, and gender with cohort 2.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with CF will be recruited from the Cystic Fibrosis Centers at Children's Hospital&#xD;
        Boston and Massachusetts General Hospital. Healthy subjects will be a community sample&#xD;
        recruited from nearby communities.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        COHORT 1&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 6 to 75 years old&#xD;
&#xD;
          -  Established diagnosis of CF with at least one abnormal G551D-CFTR allele&#xD;
&#xD;
          -  Eligibility for and intent to start treatment with ivacaftor or started treatment with&#xD;
             ivacaftor within previous 6 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychiatric or mental incapacity that would preclude subject from assenting to study&#xD;
             participation&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  History of organ transplantation&#xD;
&#xD;
          -  History of Burkholderia dolosa infection&#xD;
&#xD;
        COHORT 2:&#xD;
&#xD;
        Subjects will be grouped by gender, age and race to match subjects in Cohort 1 within two&#xD;
        years. Pubertal subjects will be matched by Tanner stage.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 6 to 75 years old&#xD;
&#xD;
          -  Established diagnosis of CF&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psychiatric or mental incapacity that would preclude subject from assenting to study&#xD;
             participation&#xD;
&#xD;
          -  Current pregnancy&#xD;
&#xD;
          -  History of organ transplantation&#xD;
&#xD;
          -  History of Burkholderia dolosa infection&#xD;
&#xD;
        COHORT 3:&#xD;
&#xD;
        Subjects will be grouped by gender, age and race to match subjects in Cohort 2 within two&#xD;
        years. Pubertal subjects will be matched by Tanner stage.&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Age 6 to 75 years old&#xD;
&#xD;
          -  Clinically stable, deemed able to complete the screening, baseline, and scheduled&#xD;
             study visits.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  History of significant cardiac, renal, pulmonary, hepatic, or malignant disease,&#xD;
             current alcohol or illicit drug abuse, or major psychiatric disorder&#xD;
&#xD;
          -  Current diagnoses known to affect bone metabolism, including cystic fibrosis,&#xD;
             osteoporosis, amenorrhea &gt;3 months (in menstruating women who are not taking oral&#xD;
             contraceptives or have an IUD), hyperthyroidism, diabetes, hyperparathyroidism,&#xD;
             Paget's disease, kidney stones, chronic inflammatory diseases, malabsorptive&#xD;
             disorders, malnutrition, prolonged immobility, and skeletal dysplasias&#xD;
&#xD;
          -  History of a non-digital fracture in the previous 6 months, history of one pathologic&#xD;
             fracture, or greater than four total lifetime non-digital fractures&#xD;
&#xD;
          -  Cumulative lifetime use of oral glucocorticoids for greater than 2 months&#xD;
&#xD;
          -  Current or prior use of medications known to affect bone metabolism including hormone&#xD;
             replacement therapy, anti-estrogens, bisphosphonates, calcitonin, fluoride, lithium,&#xD;
             suppressive doses of levothyroxine, or anticonvulsants.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  BMI less than 18.5 or greater than 30 kg/m2 in subjects 18 years and older, or BMI&#xD;
             less than 5th or greater than 95th percentile in subjects under the age of 18 years.&#xD;
&#xD;
          -  Any medical or psychiatric condition or situation that would compromise subject&#xD;
             safety, informed consent/assent, treatment compliance, follow-up measurements, or data&#xD;
             quality&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Finkelstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185.</citation>
    <PMID>22047557</PMID>
  </reference>
  <reference>
    <citation>Accurso FJ, Rowe SM, Clancy JP, Boyle MP, Dunitz JM, Durie PR, Sagel SD, Hornick DB, Konstan MW, Donaldson SH, Moss RB, Pilewski JM, Rubenstein RC, Uluer AZ, Aitken ML, Freedman SD, Rose LM, Mayer-Hamblett N, Dong Q, Zha J, Stone AJ, Olson ER, Ordoñez CL, Campbell PW, Ashlock MA, Ramsey BW. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18;363(21):1991-2003. doi: 10.1056/NEJMoa0909825.</citation>
    <PMID>21083385</PMID>
  </reference>
  <reference>
    <citation>MacNeil JA, Boyd SK. Accuracy of high-resolution peripheral quantitative computed tomography for measurement of bone quality. Med Eng Phys. 2007 Dec;29(10):1096-105. Epub 2007 Jan 16.</citation>
    <PMID>17229586</PMID>
  </reference>
  <reference>
    <citation>Aris RM, Merkel PA, Bachrach LK, Borowitz DS, Boyle MP, Elkin SL, Guise TA, Hardin DS, Haworth CS, Holick MF, Joseph PM, O'Brien K, Tullis E, Watts NB, White TB. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab. 2005 Mar;90(3):1888-96. Epub 2004 Dec 21. Review.</citation>
    <PMID>15613415</PMID>
  </reference>
  <reference>
    <citation>Shead EF, Haworth CS, Condliffe AM, McKeon DJ, Scott MA, Compston JE. Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax. 2007 Jul;62(7):650-1.</citation>
    <PMID>17600296</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 2, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2012</study_first_posted>
  <results_first_submitted>February 25, 2020</results_first_submitted>
  <results_first_submitted_qc>March 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">March 25, 2020</results_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Melissa Susan Putman</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Cystic fibrosis related bone disease</keyword>
  <keyword>Cystic fibrosis</keyword>
  <keyword>Ivacaftor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Diseases</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 28, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT01549314/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>27 subjects with CF taking ivacaftor were enrolled; however, 1 subject dropped out immediately after signing the consent form prior to any study procedures. No baseline data were obtained in this subject. Therefore, 26 subjects with CF taking ivacaftor were followed prospectively and were matched to the other 2 cohorts.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Subjects With CF Taking Ivacaftor</title>
          <description>Subjects with CF ages 6 to 75 years old who will be or have started taking ivacaftor within the previous 6 months</description>
        </group>
        <group group_id="P2">
          <title>Subjects With CF Not Taking Ivacaftor</title>
          <description>Subjects with CF ages 6 to 75 years old who will not be taking ivacaftor, matched for age, race, and gender with cohort 1</description>
        </group>
        <group group_id="P3">
          <title>Healthy Subjects</title>
          <description>Healthy subjects with no medical conditions known to affect bone between the ages of 6 to 75 years old, matched for age, race, and gender with cohort 2.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27">1 subject signed the consent form but dropped out prior to any study procedures or data collection.</participants>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subjects With CF Taking Ivacaftor</title>
          <description>Subjects with CF ages 6 to 75 years old who will be or have started taking ivacaftor within the previous 6 months</description>
        </group>
        <group group_id="B2">
          <title>Subjects With CF Not Taking Ivacaftor</title>
          <description>Subjects with CF ages 6 to 75 years old who will not be taking ivacaftor, matched for age, race, and gender with cohort 1</description>
        </group>
        <group group_id="B3">
          <title>Healthy Subjects</title>
          <description>Healthy subjects with no medical conditions known to affect bone between the ages of 6 to 75 years old, matched for age, race, and gender with cohort 2.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.1" spread="13.1"/>
                    <measurement group_id="B2" value="22.8" spread="13.1"/>
                    <measurement group_id="B3" value="23.8" spread="13.2"/>
                    <measurement group_id="B4" value="23.3" spread="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Microarchitecture and Strength Measures of the Radius and Tibia</title>
        <description>Change in cortical volumetric bone mineral density at the radius</description>
        <time_frame>Baseline and 24 months</time_frame>
        <population>Subjects who were lost to follow up prior to the 24 month visit were not included in the analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With CF Taking Ivacaftor</title>
            <description>Subjects with CF ages 6 to 75 years old who will be or have started taking ivacaftor within the previous 6 months</description>
          </group>
          <group group_id="O2">
            <title>Subjects With CF Not Taking Ivacaftor</title>
            <description>Subjects with CF ages 6 to 75 years old who will not be taking ivacaftor, matched for age, race, and gender with cohort 1</description>
          </group>
          <group group_id="O3">
            <title>Healthy Subjects</title>
            <description>Healthy subjects with no medical conditions known to affect bone between the ages of 6 to 75 years old, matched for age, race, and gender with cohort 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Microarchitecture and Strength Measures of the Radius and Tibia</title>
          <description>Change in cortical volumetric bone mineral density at the radius</description>
          <population>Subjects who were lost to follow up prior to the 24 month visit were not included in the analyses</population>
          <units>mgHA/cm3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.6" spread="53.9"/>
                    <measurement group_id="O2" value="40.1" spread="44.0"/>
                    <measurement group_id="O3" value="43.7" spread="53.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to 24 months in cortical volumentric bone mineral density was determined and compared between subjects with CF taking ivacaftor and subjects with CF not taking ivacaftor.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.77</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to 24 months in cortical volumentric bone mineral density was determined and compared between subjects with CF not taking ivacaftor and healthy subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Areal Bone Mineral Density as Measured by DXA</title>
        <description>Change in PA spine bone mineral density</description>
        <time_frame>Baseline and 24 months</time_frame>
        <population>Subjects who were lost to follow up prior to the 24 month visit were not included in the analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With CF Taking Ivacaftor</title>
            <description>Subjects with CF ages 6 to 75 years old who will be or have started taking ivacaftor within the previous 6 months</description>
          </group>
          <group group_id="O2">
            <title>Subjects With CF Not Taking Ivacaftor</title>
            <description>Subjects with CF ages 6 to 75 years old who will not be taking ivacaftor, matched for age, race, and gender with cohort 1</description>
          </group>
          <group group_id="O3">
            <title>Healthy Subjects</title>
            <description>Healthy subjects with no medical conditions known to affect bone between the ages of 6 to 75 years old, matched for age, race, and gender with cohort 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Areal Bone Mineral Density as Measured by DXA</title>
          <description>Change in PA spine bone mineral density</description>
          <population>Subjects who were lost to follow up prior to the 24 month visit were not included in the analyses</population>
          <units>g/cm2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.032" spread="0.058"/>
                    <measurement group_id="O2" value="0.024" spread="0.043"/>
                    <measurement group_id="O3" value="0.029" spread="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to 24 months in DXA PA spine bone mineral density was determined and compared between subjects with CF taking ivacaftor and subjects with CF not taking ivacaftor.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to 24 months in DXA PA spine bone mineral density was determined and compared between subjects with CF not taking ivacaftor and healthy subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.78</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Turnover Markers</title>
        <description>Change in osteocalcin</description>
        <time_frame>Baseline and 24 months</time_frame>
        <population>Subjects who were lost to follow up prior to the 24 month visit were not included in the analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Subjects With CF Taking Ivacaftor</title>
            <description>Subjects with CF ages 6 to 75 years old who will be or have started taking ivacaftor within the previous 6 months</description>
          </group>
          <group group_id="O2">
            <title>Subjects With CF Not Taking Ivacaftor</title>
            <description>Subjects with CF ages 6 to 75 years old who will not be taking ivacaftor, matched for age, race, and gender with cohort 1</description>
          </group>
          <group group_id="O3">
            <title>Healthy Subjects</title>
            <description>Healthy subjects with no medical conditions known to affect bone between the ages of 6 to 75 years old, matched for age, race, and gender with cohort 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Turnover Markers</title>
          <description>Change in osteocalcin</description>
          <population>Subjects who were lost to follow up prior to the 24 month visit were not included in the analyses</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.36" spread="12.89"/>
                    <measurement group_id="O2" value="-4.51" spread="16.27"/>
                    <measurement group_id="O3" value="-4.5" spread="14.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to 24 months in osteocalcin was determined and compared between subjects with CF taking ivacaftor and subjects with CF not taking ivacaftor.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.86</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change from baseline to 24 months in osteocalcin was determined and compared between subjects with CF not taking ivacaftor and healthy subjects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.99</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>This was an observational study following subjects prospectively over time without an intervention. Any medications, including ivacaftor, were managed by subjects' physician. Therefore, adverse events associated with this study were related to study procedures only. One subject felt lightheaded after venipuncture, improved with food and water, and this was the only adverse event reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>Subjects With CF Taking Ivacaftor</title>
          <description>Subjects with CF ages 6 to 75 years old who will be or have started taking ivacaftor within the previous 6 months</description>
        </group>
        <group group_id="E2">
          <title>Subjects With CF Not Taking Ivacaftor</title>
          <description>Subjects with CF ages 6 to 75 years old who will not be taking ivacaftor, matched for age, race, and gender with cohort 1</description>
        </group>
        <group group_id="E3">
          <title>Healthy Subjects</title>
          <description>Healthy subjects with no medical conditions known to affect bone between the ages of 6 to 75 years old, matched for age, race, and gender with cohort 2.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Minor</sub_title>
                <description>Lightheaded</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a prospective observational multiple cohort study and not a randomized or interventional clinical trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Melissa Putman</name_or_title>
      <organization>Massachusetts General Hospital Endocrine Unit</organization>
      <phone>857-218-5017</phone>
      <email>msputman@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

